Two suppressor molecules affect 70 genes in leukemiaApril 25, 2008COLUMBUS, Ohio - By restoring two small molecules that are often lost in chronic leukemia, researchers were able to block tumor growth in an animal model. The research, using human chronic lymphocytic leukemia (CLL) cells, also showed that loss of the two molecules affects 70 genes, most of which are involved in critical functions such as cell growth, death, proliferation and metabolism. The findings reveal how the two molecules, called miR-15a and miR-16-1, normally protect against cancer, and suggest a possible new treatment strategy for CLL.
The study, led by researchers at the Ohio State University Comprehensive Cancer Center, was published recently in the Proceedings of the National Academy of Sciences. "These findings give us a signature of 70 deregulated genes that we believe finally explains at the molecular level how these two molecules contribute to CLL," says principal investigator Carlo M. Croce, director of Ohio State's human cancer genetics program. "The identification of these genes could also have important significance for the development of new therapeutic approaches for chronic leukemias." The two molecules are forms of microRNA, tiny molecules that cells use to help regulate the type and amount of proteins they make. In 2005, Croce and his colleagues first showed that these two microRNAs target a gene called Bcl2, which normally helps cells survive by protecting them from accidental self-destruction. In CLL, however, the gene behaves abnormally and helps the leukemic cells survive long after they should have died. Croce and his colleagues believe that loss of the two molecules alters the gene's behavior. For the new study, the investigators first injected mice with leukemia cells in which they had restored the two microRNAs. This completely suppressed tumor growth in three of five animals. Mice injected with leukemic cells that lacked the two molecules, on the other hand, developed significant tumors. "This clearly showed that these two microRNAs can suppress tumor development," says coauthor Muller Fabrri, a researcher in Croce's laboratory. Because each microRNA regulates many genes, the investigators wanted to learn which ones, in addition to Bcl2, are affected in cells lacking the two molecules. First, they measured differences in gene activity in laboratory-grown CLL cells that had either high or low levels of the two molecules. Next, they measured the levels of all the proteins in the two groups of cells. This proteomic analysis revealed 27 proteins with highly altered amounts. These were identified and shown to be involved in cell growth, cell death and cancer development. Last, the researchers used human CLL cells from 16 patients to verify the gene targets. "Together, these extensive experiments revealed the signature of 70 genes controlled by the two microRNAs," Fabbri says. "They show that microRNAs can affect different biochemical pathways in different ways, and they explain at the molecular level what these two miRNAs do in this disease." Ohio State University Medical Center | |||||||||||||||||||||
|
Related Leukemia News Articles VCU Massey Cancer Center Spearheads Novel Clinical Study for Lymphoma Patients The Virginia Commonwealth University Massey Cancer Center recently opened a National Cancer Institute (NCI)-sponsored, phase II clinical study for certain sub-types of non-Hodgkin's lymphoma. New insights into the regulation of PTEN tumor suppression function The PTEN tumor suppressor gene controls numerous biological processes including cell proliferation, cell growth and death. But PTEN is frequently lost or mutated; in fact, alteration of the gene is so common among various types of human cancer that PTEN has become one of the most frequently mutated of all tumor suppressors. Children's national co-leads nationwide study of landmark sickle cell treatment Children's National Medical Center immunologist and blood and marrow transplant physician Naynesh Kamani, MD, will serve as the study co-chair for a new national clinical trial of unrelated donor marrow and umbilical cord blood transplants for severe sickle cell disease. Newly discovered molecular switch helps decide cell type in early embryo development Researchers have discovered a central molecular switch in fruit fly embryos that opens new avenues for studying the causes of birth defects and cancer in humans. Writing about their study in the Aug. 12 Developmental Cell, scientists at Cincinnati Children's Hospital Medical Center determined the switch to be a main tuning mechanism for instructing cells whether to form sensory nerves or blood cells in different parts of the body. McGill researchers overcome chemotherapy resistance in the lab Researchers from McGill University's Faculty of Medicine have discovered a compound that reduces resistance to chemotherapy agents used to treat cancer. Their results were published in the June issue of The Journal of Clinical Investigation (JCI). Crucial Factors in Lymphoma Development and Survival Discovered Researchers at National Jewish Medical and Research Center have discovered an important factor in the development of B-cell lymphomas, one of the fastest growing forms of cancer. Leukemia drug could save lives of stroke patients The drug tPA is the most effective treatment currently available for stroke patients, but its safety is limited to use within the first three hours following the onset of symptoms. Stroke study reveals key target for improving treatment and suggests that Gleevec may help For over a decade, the drug called tPA has proven its worth as the most effective emergency treatment for the most common kind of stroke. But its promise is blemished by two facts: tPA can cause dangerous bleeding in the brain, and its brain-saving power fades fast after the third hour of a stroke. Math could help cure leukemia When kids complain that math homework won't help them in real life, a new answer might be that math could help cure cancer. Combining math and medicine to treat leukemia Researchers have produced a mathematical model that may lead to the development of an optimally-timed vaccine for chronic myelogenous leukemia (CML). More Leukemia News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||